Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Curis Inc 128 SPRING STREET BUILDING C SUITE 500 LEXINGTON MA 02421 USA

www.curis.com Employees: 49 P: 617-503-6500

Description:

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

Key Statistics

Overview:

Market Capitalization, $K 26,078
Enterprise Value, $K -602
Shares Outstanding, K 8,467
Annual Sales, $ 10,020 K
Annual Net Income, $ -47,410 K
Last Quarter Sales, $ 2,930 K
Last Quarter Net Income, $ -10,090 K
EBIT, $ -47,750 K
EBITDA, $ -48,550 K
60-Month Beta 3.34
% of Insider Shareholders 5.70%
% of Institutional Shareholders 29.97%
Float, K 7,984
% Float 94.30%
Short Volume Ratio 0.42

Growth:

1-Year Return -74.61%
3-Year Return -97.03%
5-Year Return -90.06%
5-Year Revenue Growth -3.93%
5-Year Earnings Growth 54.29%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.70 on 11/14/24
Next Earnings Date 02/13/25
Earnings Per Share ttm -7.81
EPS Growth vs. Prev Qtr 16.26%
EPS Growth vs. Prev Year 20.19%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 09/29/23

CRIS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -923.37%
Return-on-Assets % -78.35%
Profit Margin % -473.15%
Debt/Equity 0.00
Price/Sales 2.59
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.45
Interest Coverage -22.47
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar